Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner. One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world.
The Institute for Clinical and Economic Review is hosting a three-part colloquium series of 90-minute webinars with policy makers and experts from diverse perspectives to debate alternative pricing policy approaches for current and future treatments for COVID-19.
The second colloquium will cover value-based pricing through which cost-effectiveness analysis is used set a ceiling price based on the degree of added benefit for patients and society.
Confirmed Speakers include:
- Jon Campbell, PhD, Associate Professor, Pharmaceutical Outcomes Research, University of Colorado
- Bobby Dubois, MD, PhD, Chief Science Officer and Executive Vice President, National Pharmaceutical Council
- Craig Garthwaite, PhD, Associate Professor of Strategy, Kellogg School of Management, Northwestern University
- Steve Miller, MD, Chief Clinical Officer, Cigna
- Eleanor Perfetto, PhD, Executive Vice President of Strategic Initiatives, National Health Council